EN DE
Check 35,000+ stocks against 26 valuation models and 37 quality factors
Data-driven stock valuation

Gedeon Richter PLC (0QFP) fair value: what the stock is really worth

As of Oct 2, 2026: fair value of Gedeon Richter PLC £69.27, price £50.40, upside +37.4%, quality 81 out of 100. Calculated from audited financials with 26 valuation models and 37 quality factors, updated daily.

  1. Fair value above price? Yes
  2. Good quality? Yes
  3. Add to watchlist

Healthcare · GB · Home Hungary · ISIN HU0000123096

GR Thin data Sep 28, 2026

Gedeon Richter PLC

0QFP · LSE

Undervalued, solidFair Value upside is positive and quality is strong.

✓Fair value £69.27 · Undervalued (+37.4%)
✓Quality 81/100
!Mixed Growth (revenue 3y +8.4 %/yr)
✓Highly profitable · 24.8% net margin (TTM)
✓Low debt
✓Wide moat 80/100
!Evidence only low, so the estimate is less certain
Watch Gedeon Richter PLC for free, get notified when fair value or trend changes. Plus fair value for all 35,000+ stocks, 14 days of Pro free, no card. Watch for free Pro now: $1 first month

What runs behind every stock

26 valuation models 8 families, DCF to NCAV 37 quality factors margins, balance sheet, cashflow, debt 6 AI factors moat, what no ratio measures 2,000+ data points verified, per stock, median

69 individual criteria per stock, every one traceable See the method →

Price vs Fair Value

£119.31 £50.18 Fair Value £69.27 Jul 2021 Oct 2026

White line = price, green steps = our fair value per fiscal year, dashed = 300-day average. As of Sep 28, 2026.

How to read this chart

60‑month range £50.18 – £119.31 · fair‑value band £53.15 – £85.38 · the £50.40 price screens below the £69.27 fair value. Dashed = 300-day average. As of Sep 28, 2026.

Which stocks are undervalued right now? Check free Discover now →

Company profile

Gedeon Richter PLC researches, develops, manufactures, markets, and sells pharmaceutical products. It offers women's healthcare products for contraceptives, endometriosis, fertility, menopause, vaginal infections, and uterine fibroids; and Femtech, a digital therapeutic solution to enhance women's lives.

Show more

Gedeon Richter PLC researches, develops, manufactures, markets, and sells pharmaceutical products. It offers women's healthcare products for contraceptives, endometriosis, fertility, menopause, vaginal infections, and uterine fibroids; and Femtech, a digital therapeutic solution to enhance women's lives. It also provides central nervous system products, such as products for the treatment of chronic cerebral circulatory disorders and neuropathic pain; and anaesthetics, anti-anxiety medications, sleeping pills, and anti-epileptic medicines, as well as products for the prevention and treatment of various cardiovascular diseases. In addition, it produces various over-the-counter products for various health problems comprising Panangin for heart support; Escapelle and Postinor, which are emergency contraceptive pills; Stopdiar and Nifuroxazide to treat diarrhea; RICHTER CycleBalance for infertility and PCOS; Curiosin for wound healing; Groprinosin for antiviral and immunostimulant; Folik, a pregnancy supplement; Moilec for back and joint pain; Fasconal, a pain relief tablet; Lordestin for allergies; Magnezin, a magnesium supplement; Aflamil, an anti-inflammatory and antirheumatic cream; and Oralsept, a sore throat and local anesthetic. Further, it engages in the provision of financial accounting, social and welfare, portfolio management, catering, carriage transportation, engineering, asset management, and biotechnological manufacturing and research services; pharmaceutical retail; trading of biotech products; and sale of medical equipment. It has strategic co-development and license agreement with Adalvo Ltd. for a proposed bioequivalent to Semaglutide injection, a GLP-1 receptor agonist indicated for chronic weight management. Additionally, it has a strategic research collaboration with FimmCyte AG for the development of first-in-class antibody, "FMC2', for the treatment of endometriosis. The company was founded in 1901 and is headquartered in Budapest, Hungary.

Stock analysis

Gedeon Richter PLC (0QFP) currently trades at £50.40, while our model-based Fair Value estimate is £69.27, implying the stock looks roughly 27.2% undervalued today.

Show more

Valuation

How firm this estimate is: it rests on 25 models at a data quality of 91/100, which puts the evidence level at low.

Scenario range: £53.15 (bear) to £85.38 (bull), the price of £50.40 sits below it. Bear and bull are the same models on cautious and optimistic assumptions, a range, not a price target.

Quality & growth

The Quality Score stands at 81/100 (high quality), in the Healthcare sector.

Mixed Growth: Revenue is growing, but margins or cash flow do not fully confirm the trend.

Gedeon Richter PLC reported revenue of £567B in FY2020 versus £390B in FY2016, a compound +9.8%/yr. Reported net income was £105B in FY2020, compounding +12.1%/yr from FY2016.

Key figures

Market cap £1.5T · P/S ratio 1.61 · Net margin 18.5% · Return on equity 16.4% · Return on assets (EBIT) 6.3% · Operating margin 30.6% · Revenue (TTM) £925B · Revenue growth (YoY) −1.7%.

Competitive moat

Our AI-assisted moat analysis scores the competitive advantage at 55 out of 100 (low confidence).

What moves the price

The share trades about 58% below its 52-week high and at its 52-week low, currently below its 200-day average.

For context, the median of 10 Healthcare peers we cover trades at −19% fair-value upside, at 37%, 0QFP screens cheaper than that median.

Fair Value models

Bear £53.15 Fair Value £69.27 Bull £85.38
Model ⓘEach model values the company its own way (discounted cash flow, earnings, assets, dividends). The fair value above is their evidence-weighted blend, not the output of a single model. Bear ⓘBear = the cautious scenario: the same model computed with conservative anchors (lower growth, margins and valuation multiples). Together with Bull it frames a plausible valuation range, not a price target.BaseBull ⓘBull = the optimistic scenario: the same model computed with favourable anchors (higher growth, margins and valuation multiples). Together with Bear it frames a plausible valuation range, not a price target. If a model's bull case is above four times its base value, the table shows that limit with a > sign (like the overall Bull above): beyond it no assumption holds. Evidence ⓘEvidence = how well-backed THIS model's estimate is for this stock (0–100): how complete and reliable its input data are, and how well the model fits the company. The final Fair Value is an evidence-weighted blend, so better-evidenced models count more. Green ≥70, amber 50–69, grey below 50.
Highest evidence
FCF DCF £8,777 £15,384 £27,083 74
EPV £3,894 £4,496 £5,031 74
Growth DCF £8,790 £15,093 £26,237 72
All 25 models by family
DCF Models
FCF DCF £8,777 £15,384 £27,083 74
5Y Revenue Exit £5,409 £8,230 £11,892 69
5Y EBITDA Exit £6,677 £10,790 £15,800 71
5Y P/E Exit £6,768 £10,973 £15,648 67
10Y Revenue Exit £6,332 £9,375 £13,713 63
10Y EBITDA Exit £7,305 £11,272 £16,992 64
10Y P/E Exit £7,366 £11,407 £16,865 60
Earnings-Based
Graham-Dodd £2,412 £10,364 £14,163 61
Lynch FV £2,655 £3,792 £4,930 58
PEG = 1.0 £2,655 £3,792 £4,930 55
EPV £3,894 £4,496 £5,031 74
Dividend Discount
Gordon GGM £1,367 £2,984 £5,021 63
DDM Multi-Stage £1,367 £2,445 £3,110 64
Multiples
P/E Multiple £5,853 £7,804 £9,755 63
P/S Multiple £4,523 £6,031 £7,538 58
P/B Multiple £4,523 £6,031 £7,538 55
EV/EBIT £5,315 £6,927 £8,538 66
EV/EBITDA £6,191 £8,094 £9,997 67
EV/Revenue £3,932 £5,410 £6,889 54
Asset-Based
NCAV (Graham) £1,367 £1,832 £2,735 54
Growth DCF
Growth DCF £8,790 £15,093 £26,237 72
Rev-Margin DCF £5,409 £8,248 £11,845 69
Economic Profit
Residual Income £2,642 £3,273 £4,739 72
ROIC Compounder £4,303 £5,745 £7,733 69
Growth Earnings
Growth-Adj P/E £4,564 £6,520 £8,475 65

Open the full fair value analysis →

Notify me when 0QFP reaches fair value

Put 0QFP on your watchlist. We get in touch as soon as price and fair value meet or the trend turns.

Set up alert →

Quality Score breakdown

Overall quality 81/100

Of which business quality 79 · Market factors (momentum, volatility) 37

Profitability 60
Margins and returns on capital today
Quality Growth 69
Are margins and returns improving?
Cashflow 95
Earnings quality: real cash, not paper profit
Fin. Strength 90
Balance sheet, leverage, solvency risk
Investment 76
Disciplined investing over empire-building
Low Volatility 50
Calm price path (market factor)
Momentum 40
Price trend over the last 3–12 months (market factor)
52W Momentum 17
Distance to the 52-week high (market factor)

Open the full quality analysis →

Revenue & earnings trend

Growth Quality ⓘGrowth is valuable only when reinvestment earns attractive returns (Aswath Damodaran): sustainable growth depends on return on capital, reinvestment and efficiency. Basis: total company revenue over the periods shown on the cards (3Y/5Y/all years), not per share, so a merger can show up as a growth jump; per-share earnings growth is in the value-creation card. 79/100
Revenue is growing, but margins or cash flow do not fully confirm the trend.
Revenue growth 1 year
+11.6%
Revenue growth 3 years ⓘMeasures the company's TOTAL revenue from reported annual statements: compound average growth per year (CAGR) from the fiscal year 3, 5 or N years back to the most recent comparable fiscal year. Not per share: buybacks do not change this number, and a merger can appear as a growth jump. Per-share growth (which does include buybacks) is in the value-creation card.
+8.4%
Profit margin (trend) ⓘOperating margin then vs now, from reported annual statements. A falling margin after a boom year is the classic peak-earnings signal: the growth rate then leans on an inflated base.
14.0% (2016) → 19.7% (2020)
What shareholders gained per year ⓘWe only publish this rate when it is defensible. Reason: no share-count history
not computed

Watch 0QFP, get fair value alerts →

Compare Gedeon Richter PLC with another stock

Price, fair value, quality and upside side by side.

Free, no sign-up

Peer GroupⓘHow this stock ranks against its industry: the green marker is this stock, the band is the typical 25–75% peer range, and the tick is the median.Drug Manufacturers - Specialty & Generic · 569 stocks

Beats the industry median on 7/11 measures
Overall it ranks above its industry peers.
Valuation
Quality Score 81 · Top 25%
Fair Value upside +37.4% · Top 25%
Profitability
Return on equity (TTM) 16.4% · Top 25%
Return on assets 11.0% · Top 25%
Net margin (TTM) 24.8% · Top 25%
Operating margin (TTM) 30.6% · Top 25%
Growth and dividend
Revenue growth −1.7% · Below median
Dividend yield (TTM) 0.0% · Bottom 25%

Valuation Multiplesvs Drug Manufacturers - Specialty & Generic median · lower = cheaper

P/B 2.49× · Pricier than median
P/S (TTM) 2.17× · Pricier than median
EV/EBITDA 5.3× · Cheapest 25%

Context: sector, industry, market

Values & ESG

Does this company touch areas you may want to avoid? The classification is inferred from sector and industry.

None of the checked exposures detected

Similar stocks

10 more Drug Manufacturers - Specialty & Generic stocks, each showing price versus our Fair Value estimate.

Stock Price Fair Value vs Fair Value
Merck KGaA MRK €134.45 €108.94 −19%
Takeda Pharmaceutical Company TAK $18.90 $11.45 −39%
Teva Pharmaceutical Industries Limited TEVA $39.31 $20.88 −47%
Sun Pharmaceutical Industries Limited SUNPHARMA ₹1,852 ₹1,979 +7%
Galderma Group GALD CHF 163.00 CHF 110.32 −32%
Jiangsu Hengrui Pharmaceuticals Co 600276 ¥44.86 ¥49.35 +10%
Haleon plc HLN $9.26 $8.49 −8%
Sandoz Group SDZ CHF 71.16 CHF 40.32 −43%
Zoetis Inc ZTS $70.30 $110.50 +57%
Divi's Laboratories Limited DIVISLAB ₹9,620 ₹1,871 −81%

Explore undervalued stocks

More undervalued Healthcare stocks →

All undervalued stocks TechnologyFinancial ServicesHealthcareConsumer CyclicalConsumer DefensiveCommunication ServicesIndustrialsEnergyBasic MaterialsReal EstateUtilities Deeply Undervalued StocksUndervalued High-Quality StocksUndervalued Blue-Chip StocksUndervalued Small-Cap StocksUndervalued Dividend Stocks

Try a ready-made strategy

Pick a strategy and jump into the live analysis with that exact screen applied.

🥇 Backtested Best 🏆 Big Names ⭐ Top Rated 💎 Quality on Sale 🚀 Profitable Growth 🧊 Quality Compounders 💵 Dividend Stars 📈 Strong Momentum 📉 Fallen Angels ⚖️ Deeply Undervalued 🔍 Small-Cap Gems 🏰 Moat at a Fair Price 💼 Insider Buying 🎩 Buffett-Style Quality 📚 Peter Lynch GARP 🧮 Greenblatt Magic Formula 🛡️ Graham Defensive

Discover tools

Stock screenerFilter by region, size and sector Compare toolTwo stocks side by side Extrinsic Value Calculator…Calculator with industry benchmark Peter Lynch Fair Value Formula &…Calculator with industry benchmark
Run the numbers yourself: free valuation calculators
DCF CalculatorGraham NumberPeter Lynch FormulaDDM CalculatorFama-French ModelIntrinsic Value
For bloggers & editors: embed code + live data

For bloggers, editors and developers: paste this into your site or blog (a “Custom HTML” block in WordPress), it shows the current fair value and links back here. Free, plain HTML, and welcome. Full data streams (CSV/JSON) at /developers.

Gedeon Richter PLC · Fair Value
£69.27 +27%Fair Value
Calculator →

Cite: Fair Value Calculator (2026). "Gedeon Richter PLC Fair Value". https://www.fairvalue-calculator.com/stock/0QFP

Frequently asked questions

Is Gedeon Richter PLC (0QFP) overvalued or undervalued?
As of Sep 28, 2026, our model estimates a fair value of £69.27 versus a price of £50.40, about +37% upside (undervalued).
What is the fair value of 0QFP?
Our model-based fair value for Gedeon Richter PLC is £69.27 (as of Sep 28, 2026), built from audited fundamentals. The current price: £50.40.
What is the quality score of 0QFP?
Gedeon Richter PLC has a Quality Score of 81/100. It measures business quality (profitability, growth, cash flow, balance-sheet strength, investment discipline, share issuance). Market factors such as price momentum and volatility do not enter the number; they are shown separately in the detail view.
What is the price target for Gedeon Richter PLC (0QFP)?
Our model-based price target is the fair value of £69.27 (as of Sep 28, 2026) from 25 valuation models. Cautious scenario £53.15, optimistic scenario £85.38. It is a calculation from audited fundamentals, not an analyst target.
What is the Gedeon Richter PLC stock forecast for 2026?
Our models put fair value at £69.27, about +37% upside versus a price of £50.40 (undervalued). Cautious scenario £53.15, optimistic scenario £85.38. The calculation is refreshed regularly with new filings.
What is the revenue of Gedeon Richter PLC (0QFP)?
Gedeon Richter PLC reported trailing-twelve-month revenue of about £925B (latest available figure, as of Sep 28, 2026).
What is the intrinsic value of Gedeon Richter PLC (0QFP)?
Intrinsic value and fair value mean the same thing: what the business is worth on its numbers, independent of the share price. For Gedeon Richter PLC it is £69.27 per share (as of Sep 28, 2026), against a price of £50.40. It is the blended result of 25 valuation models (cash flow, earnings, asset, dividend).
Is Gedeon Richter PLC stock overvalued or undervalued in 2026?
As of Sep 28, 2026, 0QFP trades below its calculated fair value: price £50.40, fair value £69.27, a gap of about +37% (undervalued). The calculation is refreshed with each new quarterly report, so the verdict can change during the year.
Is fair value the same as the market price of 0QFP?
No. The price is what the market pays today (£50.40); the fair value is what the company's own numbers justify (£69.27). For Gedeon Richter PLC the two are £18.87 per share apart. That gap is exactly why we show both numbers side by side.
How much is Gedeon Richter PLC worth?
The market values Gedeon Richter PLC at about £1.5T (market capitalisation, as of Sep 28, 2026). Per share that is £50.40; our models calculate a fair value of £69.27 per share.
What do the bullish and bearish scenarios say about 0QFP?
Our models span a range for Gedeon Richter PLC: cautious scenario £53.15, base £69.27, optimistic £85.38 per share (as of Sep 28, 2026, price £50.40). The range comes from different growth and margin assumptions, not from analyst opinions.
How solid is the balance sheet of Gedeon Richter PLC (0QFP)?
Balance-sheet figures for Gedeon Richter PLC (as of Sep 28, 2026): return on equity 16.4%. They feed the Quality Score of 81/100, which measures business quality independently of the share price.
How far is 0QFP from its 52-week high?
Gedeon Richter PLC trades at £50.40, about 58% below its 52-week high of £119.31 and at the low of £50.33 (as of Oct 2, 2026). Distance from the high says nothing about value: that is what the fair value of £69.27 is for.
Which stocks are comparable to Gedeon Richter PLC?
From the same area (Healthcare) we also value Merck KGaA, Takeda Pharmaceutical Company, Teva Pharmaceutical Industries Limited, Sun Pharmaceutical Industries Limited, among others. Each of them has its own fair-value calculation on this site using the same models, so the comparison is like for like.
Is Gedeon Richter PLC stock attractive at the current price?
The data as of Sep 28, 2026: price £50.40, calculated fair value £69.27 (+37%), Quality Score 81/100, from 25 models. Whether that fits your horizon and risk tolerance is your call. We provide the calculation, not investment advice.
How is the fair value of 0QFP calculated?
We run Gedeon Richter PLC through 25 models from four families: discounted cash flow, earnings models, asset and balance-sheet models, and dividend models. Every model gets the same audited fundamentals; the result is the weighted average of £69.27, with the spread shown as a cautious and an optimistic scenario.
Is it still worth investing in stocks now?
The global stock market currently sits 14.5 % above its aggregate fair value. Gedeon Richter PLC currently trades 27 % below its own fair value, and the market average says nothing about that. An expensive market is no reason to stay out and no reason to buy everything at once: keep a broad savings plan running, buy single stocks only with money you can do without, and hold part of your money liquid while the market is high. The full picture including sectors is on is it worth investing now.
What is the share price of Gedeon Richter PLC (0QFP)?
The closing price on Oct 2, 2026 was £50.40. Our model-based fair value is £69.27, about +37% upside (undervalued). We carry closing prices from our data provider, not a live tick.
What should I pay attention to with Gedeon Richter PLC right now?
The rarer combination: high quality (81/100) AND below fair value. That earns a closer look rather than a quick verdict. The price is below even our cautious bear case (£53.15). The market is more pessimistic than our downside scenario. The large gap to fair value rests on thin data (low evidence): fewer applicable models and a shorter history. Read it with extra caution.

Key figures of Gedeon Richter PLC

How large is the market capitalisation of Gedeon Richter PLC (0QFP)?
The market capitalisation of Gedeon Richter PLC is £1.5T. The stock-market value of the whole company: share price times number of shares. It is what the market asks for the entire business today.
What is the P/S ratio of Gedeon Richter PLC (0QFP)?
The price-to-sales ratio of Gedeon Richter PLC is 1.61 (last twelve months). Price to sales: market value relative to yearly revenue. Useful when profit is thin or distorted.
What is the net margin of Gedeon Richter PLC (0QFP)?
The net margin of Gedeon Richter PLC is 18.5% (fiscal year 2020). How much of every unit of revenue ends up as profit. 10% means 10 cents of profit per dollar of sales.
What is the return on equity of Gedeon Richter PLC (0QFP)?
The return on equity (ROE) of Gedeon Richter PLC is 16.4% (last twelve months). Profit relative to shareholders' equity, how efficiently the company works with its owners' money.
What is the EBIT return on assets of Gedeon Richter PLC (0QFP)?
On an EBIT basis the return on assets of Gedeon Richter PLC is 6.3% (avg 5y). Operating profit (EBIT) relative to everything the company owns, as a multi-year average. It describes the business model rather than one good or bad year.
What is the operating margin of Gedeon Richter PLC (0QFP)?
The operating margin of Gedeon Richter PLC is 30.6% (last twelve months). Profit from the core business (before interest and taxes) relative to revenue.
How fast is revenue growing at Gedeon Richter PLC (0QFP)?
Revenue at Gedeon Richter PLC is growing −1.7% versus a year earlier (3y avg +8.4%). How much revenue grew versus a year earlier (YoY). The 3-year average next to it puts the single year in context.
How fast are earnings growing at Gedeon Richter PLC (0QFP)?
Earnings per share at Gedeon Richter PLC are growing −4.3% versus a year earlier. How much earnings per share grew versus a year earlier.
Free · no account needed

Watch Gedeon Richter PLC in the live analysis

One click puts Gedeon Richter PLC on your watchlist: fair value and trend at a glance, plus comparison, the diversification check and the 35,000+ stock screener. You can also try 14 days of Pro there, no card.

Watch for free →

Zero risk: nothing is ever charged. Your watchlist is yours, with or without an account.